All the news Showing 10 of 217 articles from: Pharmaceutical industryGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources How Much Should Hepatitis C Treatment Cost? New York Times (editorial) / 18 March 2014 Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C Gilead press release / 11 February 2014 Gilead to license hepatitis C drug to lower-cost manufacturers in India Reuters / 06 February 2014 Abbvie Strong Hep C Drug Data and the Looming Battle With Gilead Sciences The Street / 03 February 2014 At $84000 Gilead Hepatitis C Drug Sets Off Payer Revolt Bloomberg / 27 January 2014 Only just the beginning of the end of hepatitis C The Lancet (editorial) / 26 January 2014 Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill Bloomberg / 14 January 2014 What Is a Hepatitis C Drug Worth? Roll Call / 14 January 2014 Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency Bristol-Myers Squibb press release / 08 January 2014 Gilead Sales Chief Retires Amidst Key Hep C Drug Launch, Massive Insider Selling The Street / 07 January 2014 ← Prev1...1819202122Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Noticeboard Email bulletins News feeds